Finance

Lists
BIIB34:BVMF
Biogen Inc BDR
R$172,75
0,00%
(0,00) 1D
28 ກ.ລ., 14 ໂມງ 23 ນາທີ 04 ວິນາທີ GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Mkt. cap
໓໐,໘໐ ຕື້
Avg. vol.
໓໙,໐໐
Volume
໐,໐໐
52-wk high
R$187,20
52-wk low
R$117,24
Shares outstanding
໑໔໗,໗໕ ລ້ານ
No. of employees
໘ ພັນ
Mkt. cap
໓໐,໘໐ ຕື້
Avg. vol.
໓໙,໐໐
Volume
໐,໐໐
52-wk high
R$187,20
52-wk low
R$117,24
Shares outstanding
໑໔໗,໗໕ ລ້ານ
No. of employees
໘ ພັນ
News stories
From sources across the web
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5 ພັນ
Founded1978
Headquartersແຄມບຣິກ, ມາຊາຊູເຊັດ, ສະຫະລັດ
SectorBiotechnology
Websitebiogen.com
Last report
29 ກ.ລ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$3,60 / US$2,03
+77,38%beat
Revenue / Est. (USD)
໒,໗໔ ຕື້ / ໒,໔໖ ຕື້
+11,19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
2,53 ຕື້
2,28 ຕື້
2,48 ຕື້
2,74 ຕື້
Cost of goods sold
508,60 ລ້ານ
443,40 ລ້ານ
610,20 ລ້ານ
611,60 ລ້ານ
Cost of revenue
508,60 ລ້ານ
443,40 ລ້ານ
610,20 ລ້ານ
611,60 ລ້ານ
Research and development expenses
431,80 ລ້ານ
477,10 ລ້ານ
482,20 ລ້ານ
492,10 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
592,80 ລ້ານ
685,20 ລ້ານ
607,30 ລ້ານ
709,70 ລ້ານ
Operating expense
1,25 ຕື້
1,36 ຕື້
1,30 ຕື້
1,44 ຕື້
Total operating expenses
1,76 ຕື້
1,81 ຕື້
1,91 ຕື້
2,05 ຕື້
Operating income
778,60 ລ້ານ
471,60 ລ້ານ
567,40 ລ້ານ
685,60 ລ້ານ
Other non operating income
15,80 ລ້ານ
17,40 ລ້ານ
-1,10 ລ້ານ
3,00 ລ້ານ
EBT including unusual items
557,30 ລ້ານ
-56,00 ລ້ານ
377,70 ລ້ານ
132,40 ລ້ານ
EBT excluding unusual items
748,30 ລ້ານ
447,00 ລ້ານ
530,10 ລ້ານ
625,10 ລ້ານ
Income tax expense
90,80 ລ້ານ
-7,10 ລ້ານ
58,20 ລ້ານ
34,90 ລ້ານ
Effective tax rate
16,29%
12,68%
15,41%
26,36%
Other operating expenses
87,20 ລ້ານ
69,90 ລ້ານ
74,20 ລ້ານ
68,80 ລ້ານ
Net income
466,50 ລ້ານ
-48,90 ລ້ານ
319,50 ລ້ານ
97,50 ລ້ານ
Net profit margin
18,40%
-2,15%
12,89%
3,56%
Earnings per share
4,81
1,99
3,57
3,60
Interest and investment income
31,60 ລ້ານ
37,20 ລ້ານ
37,90 ລ້ານ
25,30 ລ້ານ
Interest expense
-67,40 ລ້ານ
-67,50 ລ້ານ
-67,60 ລ້ານ
-82,30 ລ້ານ
Net interest expenses
-35,80 ລ້ານ
-30,30 ລ້ານ
-29,70 ລ້ານ
-57,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
980,80 ລ້ານ
671,80 ລ້ານ
771,80 ລ້ານ
921,70 ລ້ານ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google